Replies to post #683845 on NorthWest Biotherapeutics Inc (NWBO)

[georgebailey]

Anyone think there’s an Eden’s deal coming in addition to L deals? I’m starting to think that’s a certainty and near MHRA approval date.
Form 10K, pages 23 and 24, Flaskworks and intellectual property and Sawston headings.
They are possibly in-licensing for Eden’s this can be a revenue stream.The entire BP industry is ramping for cell therapy (Dstock)and Eden’s is the first automated machine doing that. How much $$ will Eden’s save BP doing clinical trials? How does a a sizable up front payment for Eden’s licensing sound to everyone? There’s a big part of management discussion citing Flaskworks /Sawston GMP facility increasing value and described as major.

[Nemesis18]

You may as well just blindfold yourself, and stick a pin in a calendar 📆.
My opinion is, is if DCVAX-L isn’t granted Marketing Approval shortly after the next CHM meeting, it’s it’s in trouble imho
Because unlike the Phase III Trial, there is no one on hand to help it across the line.

The posted results now standalone, whilst undergoing rigorous scrutiny by Regulatory Investigators, whose reason for being is just to find the smallest detail errors, or discrepancies in how pockets of data were derived at.

Imagine presenting your ear for examination. They will go in through you arse to get a closer look 👂 👀